Literature DB >> 25214562

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

Eric B Haura1, Uwe Rix2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25214562      PMCID: PMC5072366          DOI: 10.1093/jnci/dju250

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  27 in total

1.  Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

Authors:  Lecia V Sequist; Benjamin Besse; Thomas J Lynch; Vincent A Miller; Kwok K Wong; Barbara Gitlitz; Keith Eaton; Charles Zacharchuk; Amy Freyman; Christine Powell; Revathi Ananthakrishnan; Susan Quinn; Jean-Charles Soria
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis.

Authors:  Christopher Chidley; Hirohito Haruki; Miriam Grønlund Pedersen; Evelyne Muller; Kai Johnsson
Journal:  Nat Chem Biol       Date:  2011-04-17       Impact factor: 15.040

3.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

4.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Authors:  Peter S Hammerman; Martin L Sos; Alex H Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E Brace; Brittany A Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R Simard; Michael S Lawrence; Robert C Onofrio; Helga B Salvesen; Danila Seidel; Thomas Zander; Johannes M Heuckmann; Alex Soltermann; Holger Moch; Mirjam Koker; Frauke Leenders; Franziska Gabler; Silvia Querings; Sascha Ansén; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Odd Terje Brustugun; Aslaug Helland; Iver Petersen; Joachim H Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erich Stoelben; Jürgen Wolf; David G Beer; Ming Sound Tsao; Megan Hanna; Charles Hatton; Michael J Eck; Pasi A Janne; Bruce E Johnson; Wendy Winckler; Heidi Greulich; Adam J Bass; Jeonghee Cho; Daniel Rauh; Nathanael S Gray; Kwok-Kin Wong; Eric B Haura; Roman K Thomas; Matthew Meyerson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

5.  A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.

Authors:  Jiannong Li; Uwe Rix; Bin Fang; Yun Bai; Arthur Edwards; Jacques Colinge; Keiryn L Bennett; Jingchun Gao; Lanxi Song; Steven Eschrich; Giulio Superti-Furga; John Koomen; Eric B Haura
Journal:  Nat Chem Biol       Date:  2010-02-28       Impact factor: 15.040

6.  Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.

Authors:  Wen Gao; Michael Wang; Li Wang; Haibo Lu; Shuhong Wu; Bingbing Dai; Zhishuo Ou; Liang Zhang; John V Heymach; Kathryn A Gold; John Minna; Jack A Roth; Wayne L Hofstetter; Stephen G Swisher; Bingliang Fang
Journal:  J Natl Cancer Inst       Date:  2014-09-10       Impact factor: 13.506

7.  Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.

Authors:  Vincenzo Pitini; Carmela Arrigo; Cristian Di Mirto; Patrizia Mondello; Giuseppe Altavilla
Journal:  Lung Cancer       Date:  2013-08-09       Impact factor: 5.705

8.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

9.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.

Authors:  Georg E Winter; Uwe Rix; Scott M Carlson; Karoline V Gleixner; Florian Grebien; Manuela Gridling; André C Müller; Florian P Breitwieser; Martin Bilban; Jacques Colinge; Peter Valent; Keiryn L Bennett; Forest M White; Giulio Superti-Furga
Journal:  Nat Chem Biol       Date:  2012-09-30       Impact factor: 15.040

View more
  4 in total

1.  Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Authors:  Jun Li; Wei Zhao; Rehan Akbani; Wenbin Liu; Zhenlin Ju; Shiyun Ling; Christopher P Vellano; Paul Roebuck; Qinghua Yu; A Karina Eterovic; Lauren A Byers; Michael A Davies; Wanleng Deng; Y N Vashisht Gopal; Guo Chen; Erika M von Euw; Dennis Slamon; Dylan Conklin; John V Heymach; Adi F Gazdar; John D Minna; Jeffrey N Myers; Yiling Lu; Gordon B Mills; Han Liang
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

Review 2.  Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer.

Authors:  Ramanathan Karuppasamy; Shanthi Veerappapillai; Sayoni Maiti; Woong-Hee Shin; Daisuke Kihara
Journal:  Semin Cancer Biol       Date:  2019-11-04       Impact factor: 17.012

Review 3.  Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.

Authors:  Robert Campbell; Geoffrey Chong; Eliza A Hawkes
Journal:  J Clin Med       Date:  2018-03-21       Impact factor: 4.241

Review 4.  Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

Authors:  Vinayak Palve; Yi Liao; Lily L Remsing Rix; Uwe Rix
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.